SANTA BARBARA, Calif., June 01, 2021 (GLOBE NEWSWIRE) – Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical esthetics company focused solely on plastic surgeons, today announced hui the appointment of Denise Dajles as vice president of research and development, effective today. In this new role, Ms. Dajles will report to CEO Ron Menezes and lead Sientra’s R&D and medical affairs teams.
“We are delighted to welcome Denise to the Sientra leadership team,” said Ron Menezes, President and CEO of Sientra. “With her considerable technical and international expertise, Denise is uniquely positioned to lead our R&D organization as we pursue our goal of being the leader in bringing to market treatments and processing technologies that advance the art of plastic surgery. I have no doubts that Denise will provide the leadership and strategic direction to enable us to advance our development of proprietary innovations that improve the way plastic surgeons care for their patients. “
Most recently, Ms. Dajles served as Senior Director of Research, Development and Innovation heading the Science and Technology Department at Establishment Labs. In this role, she was responsible for the successful execution of more than ten new product and technology projects, which includes multiple regulatory approvals for commercialization in the United States, Europe, Latin America and Asia-Pacific, as well than the direction of in-depth scientific research. Previously, Ms. Dajles was a consultant, researcher and acting director of the Biomedical Engineering Laboratory at the Faculty of Engineering at the University of Costa Rica.
“Sientra’s unparalleled clinical data over 10 years provides an ideal platform for advancing the art of plastic surgery that combines innovation with clinically proven safety. I was immediately impressed with Sientra’s team, culture, board and drive for innovation, ”said Ms. Dajles. “I am delighted to join one of the fastest growing aesthetic medicine companies. I look forward to working with the R&D team and contributing to the long term growth of the company. “
Ms. Dajles holds a BSc and MSc in Biomedical Engineering from the University of Washington, St. Louis, and is expected to receive a PhD in Engineering from George Washington University, Washington DC in 2022. She is co-author of several publications. in peer-reviewed journals and is a named inventor on a number of technologies.
Based in Santa Barbara, California, Sientra is a medical aesthetics company focused solely on plastic surgeons. The Company’s mission is to deliver exclusive innovations and unprecedented partnerships that radically advance the way plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory tests and strong clinical trial results. The Company’s Breast Products segment includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its revolutionary Allox2® breast tissue expander with patented dual port technology and for full drainage, and BIOCORNEUM®, the # 1 high-performance healing gel, preferred and recommended by plastic surgeons
Sientra uses its investor relations website to post important information about the Company, including information that may be considered important to investors. Financial and other information about Sientra is regularly published and can be accessed on the Company’s investor relations website at www.sientra.com.
Data on file
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on current assumptions management and expectations of future events. and trends, which affect or may affect the business, strategy, operations or financial performance of the Company, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. date of this publication. The words “believe”, “can”, “could”, “could”, “can”, “aim”, “estimate”, “continue”, “anticipate”, “intend”, “‘wait”, “Plan”, “position” or the negative of these terms, and similar expressions that convey uncertainty about future events or results are intended to identify estimates, projections and other forward-looking statements. Forward-looking statements may include information regarding the Company’s development of proprietary innovations, its commercialization of new treatments and technologies, and the Company’s long-term growth. These statements are subject to risks and uncertainties, including the Company’s ability to execute its product portfolio, regulatory approval of any new proprietary innovation, and acceptance of new technologies and treatments by plastic surgeon customers and customers. patients of the Society. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s public filings with the Securities and Exchange Commission. All statements other than statements of historical fact are forward-looking statements. The words “believe”, “may”, “could”, “could”, “will”, “aim”, “estimate”, “continue”, “,”, “intend”, “‘. position “, or the negative of these terms, and similar expressions which convey uncertainty about future events or results are intended to identify estimates, projections and other forward-looking statements. You are cautioned not to rely on unduly to such forward-looking statements, and such estimates, projections and other forward-looking statements speak only as of the date on which they were made, and, except to the extent required by law, the Company assumes no obligation to update or revise any estimate, projection or forward-looking statement Actual results may differ from those presented in this press release due to the risks and uncertainties inherent in the Company’s business.
Investor Relations Contact
Leigh Salve [email protected]